Cevostamab Shows Promise in Hard-to-Treat Multiple Myeloma: Early CAMMA 2 Trial Results

Cevostamab, a FcRH5xCD3 bispecific antibody, has shown promising activity in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM), including those with prior exposure to BCMA-targeted agents. The Phase I/II CAMMA 2 study is evaluating the efficacy and safety of cevostamab in RRMM patients who are triple-class refractory and have received a prior BCMA-targeted antibody-drug conjugate (ADC) or chimeric antigen receptor (CAR) T-cell therapy. In Cohort A1 of the study, 21 patients (median age: 64 years) were enrolled, with 10 patients having received a prior ADC and 11 patients having received a prior CAR T-cell therapy. The median prior lines of therapy for these patients was 6. Among all patients, an overall response rate (ORR) of 67% was achieved, with 38% achieving a very good partial response (VGPR) or better. The ORR and VGPR or better rates were higher in the prior CAR T-cell group compared to the prior ADC group. Grade 3-4 adverse events occurred in 62% of patients, with neutropenia, anemia, and thrombocytopenia being the most common. Infections occurred in 38% of patients, with 10% being grade 3-4. Serious adverse events occurred in 48% of patients, with neutropenia being the most common. Cytokine release syndrome (CRS) occurred in 71% of patients, all of which were grade 1-2. The percentage of MMPCs expressing BCMA was higher in the prior ADC group compared to the prior CAR T-cell group. Overall, the initial data from Cohort A1 of CAMMA 2 demonstrate that cevostamab has promising activity and manageable safety in RRMM patients who are triple-class refractory and have received a prior BCMA-targeted ADC or CAR T-cell therapy.
Key Points:
- Cevostamab, a FcRH5xCD3 bispecific antibody, has shown promising activity in heavily pre-treated RRMM patients.
- The CAMMA 2 study is evaluating the efficacy and safety of cevostamab in RRMM patients who are triple-class refractory and have received a prior BCMA-targeted ADC or CAR T-cell therapy.
- In Cohort A1 of the study, 21 patients were enrolled, with 10 patients having received a prior ADC and 11 patients having received a prior CAR T-cell therapy.
- The overall response rate (ORR) was 67%, with 38% achieving a very good partial response (VGPR) or better.
- The ORR and VGPR or better rates were higher in the prior CAR T-cell group compared to the prior ADC group.
- Grade 3-4 adverse events occurred in 62% of patients, with neutropenia, anemia, and thrombocytopenia being the most common.
- Infections occurred in 38% of patients, with 10% being grade 3-4.
- Serious adverse events occurred in 48% of patients, with neutropenia being the most common.
- Cytokine release syndrome (CRS) occurred in 71% of patients, all of which were grade 1-2.
- The percentage of MMPCs expressing BCMA was higher in the prior ADC group compared to the prior CAR T-cell group.
- The initial data from Cohort A1 of CAMMA 2 demonstrate that cevostamab has promising activity and manageable safety in RRMM patients who are triple-class refractory and have received a prior BCMA-targeted ADC or CAR T-cell therapy.
Authors:
Shaji Kumar, Jesus Berdeja, Douglas Sborov, Paolo Corradini, Yael Cohen, Alexander Lesokhin, Moshe Gatt, Laura Paris, Laura Rosiñol, Hang Quach, Joshua Richter, Ameet Mishra, Oliver Catalani, Katerina Chineneyze, Paresh Sewpaul, Elisabeth Wassner Fritsch, Michel Delforge
EHA Abstract#S210
_______________
Improving Lives | Finding the Cure
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Subscribe to our channel: / imfmyeloma
Visit our website at: www.myeloma.org
Find us online:
Facebook: @myeloma | / myeloma
Twitter: @IMFMyeloma | / imfmyeloma
Instagram: @imfmyeloma | / imfmyeloma
LinkedIn: / international-myeloma-...
Support the IMF | Donate Now! fundraise.myel...
Category
Nonprofits & Activism
License
Standard CZcams License
In most cases, captions are autogenerated by CZcams.

[@matthewgraham2546]

I'm 72 years old have MM with fractured vertebrae so I am thankful for the videos. Some of the accents are a little hard to understand so the sub titles are very helpful.